Ignite Creation Date:
2024-05-05 @ 11:16 PM
Last Modification Date:
2024-10-26 @ 10:31 AM
Study NCT ID:
NCT01296451
Status:
COMPLETED
Last Update Posted:
2016-04-26
First Post:
2011-02-09
Brief Title:
Study of a New MVA Vaccine for Hepatitis C Virus
Sponsor:
ReiThera Srl
Organization:
ReiThera Srl
Study Overview
Official Title:
A Phase I Study to Assess the Safety and Immunogenicity of AdCh3NSmut and MVA-NSmut in Healthy Volunteers and Patients With Hepatitis C Virus Infection
Status:
COMPLETED
Status Verified Date:
2016-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study is aimed at assessing the safety of AdCh3NSmut and the new candidate vaccine MVA-NSmut when administered sequentially or alone to healthy volunteers and patients with hepatitis C virus infection The study also aims at assessing the cellular immune response generated by AdCh3NSmut and MVA-NSmut administered as mentioned above
Detailed Description:
The scientific rationale supporting this study can be summarised as follows an effective antiviral T cell response can mediate HCV viral control and induce the spontaneous resolution of HCV during primary infection This observation strongly supports the case for the development of T cell induction strategies as a potential therapy for HCV A hallmark of persistent HCV infection when viral loads are high is a weak and narrowly focused HCV specific T cell response whereas in resolved infection with undetectable viral loads robust T cell responses are detected Furthermore mouse and other human models of persistent viral infection show that antigen load crucially determines the quality and quantity of the anti-viral T cell responses so generated 17-18 This supports the case for the assessment of efficacy of T cell induction a in the setting of low viral loads following viral suppression with combination therapy and b in the setting of high viral loads Since pre-existing anti-vector immunity to adenoviral vectors may limit vaccine efficacy we have conducted a phase-I clinical trial in healthy human subjects using human Ad6 and simian AdCh3 adenoviral vectors found at low sero-prevalence in human populations in a heterologous primeboost regimen study HCV001 The same vectors are also under investigation in HCV infected patients HCV002 These vectors encode the HCV non-structural proteins with a genetically inactivated polymerase gene NSmut We have shown that both vectors are safe and highly immunogenic In preclinical primate studies using identical vectors heterologous boosting increased peak responses and long-term immunity However in humans it appears that although HCV specific T-cell responses increase following boosting the magnitude of this response is reduced compared to that observed during vaccine priming This is probably due to the induction of cross-reactive immunity between the two vectors In contrast it has recently been shown that Modified Vaccinia Ankara MVA encoding the malaria antigen ME-TRAP very successfully boosts T-cell responses primed with a simian Adenovirus vector inducing the highest level of CD4 and CD8 T-cell responses ever observed using a vectored vaccine and affording protection from malaria infection A Hill unpublished data
For these reasons we now wish to assess an MVA construct encoding HCV NS that will be combined with AdCh3NSmut or AdCh3NSmut1 in a heterologous primeboost vaccination regimen to assess the safety and immunogenicity of this strategy in healthy and HCV infected patients This study will address the following questions In healthy volunteers
1 Can vaccination with MVA-NSmut vector alone safely induce HCV specific T cell responses
2 Can vaccination using a heterologous primeboost vaccination schedule with AdCh3NSmut and MVA-NSmut safely induce HCV specific T cell responses
In HCV infected patients can a heterologous primeboost vaccination schedule using AdCh3NSmut and MVA-NSmut
3 Safely induce HCV specific T cell responses during pegylated-interferon and ribavirin combination therapy for HCV genotype-1 infection after a significant decline in viral load 14 weeks into therapy
4 Safely induce HCV specific T cell responses during combination therapy for HCV genotype-1 infection 2 weeks into therapy
5 Safely induce HCV specific T cell responses in patients with chronic HCV not receiving combination therapy and a high viral load
6 Suppress viral load in patients with chronic HCV not on treatment with IFN and Ribavirin Since the effect of combination therapy on HCV specific T cells is currently debated see below we will compare the T cell responses generated by the therapeutic primeboost vaccination schedule in this study to a group of matched historical control patients treated with combination therapy in whom immunological assessment has been made in an identical way to that proposed in this study
For these reasons we now wish to assess an MVA construct encoding HCV NS that will be combined with AdCh3NSmut or AdCh3NSmut1 in a heterologous primeboost vaccination regimen to assess the safety and immunogenicity of this strategy in healthy and HCV infected patients This study will address the following questions In healthy volunteers
1 Can vaccination with MVA-NSmut vector alone safely induce HCV specific T cell responses
2 Can vaccination using a heterologous primeboost vaccination schedule with AdCh3NSmut and MVA-NSmut safely induce HCV specific T cell responses
In HCV infected patients can a heterologous primeboost vaccination schedule using AdCh3NSmut and MVA-NSmut
3 Safely induce HCV specific T cell responses during pegylated-interferon and ribavirin combination therapy for HCV genotype-1 infection after a significant decline in viral load 14 weeks into therapy
4 Safely induce HCV specific T cell responses during combination therapy for HCV genotype-1 infection 2 weeks into therapy
5 Safely induce HCV specific T cell responses in patients with chronic HCV not receiving combination therapy and a high viral load
6 Suppress viral load in patients with chronic HCV not on treatment with IFN and Ribavirin Since the effect of combination therapy on HCV specific T cells is currently debated see below we will compare the T cell responses generated by the therapeutic primeboost vaccination schedule in this study to a group of matched historical control patients treated with combination therapy in whom immunological assessment has been made in an identical way to that proposed in this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2009-018260-10 | EUDRACT_NUMBER | None | None |